Every time a new observational data point appears, the reaction is the same: Instant celebration. Instant amplification. Zero skepticism. Doctors should be the guardrails in moments like this. Instead, many are becoming megaphones for half-baked narratives that generate attention but not accuracy. GLP-1s are already drowning in hype.Weight loss! Heart benefits! Now, anti-cancer powers? Except…
Every few weeks, a new headline seems to push GLP-1 drugs—Semaglutide and Tirzepatide—deeper into “miracle drug” territory. Weight loss. Heart benefits. Reduced inflammation. Better metabolic markers. And now… longer survival for colon cancer patients? A recently circulated data point claims that colon cancer patients using Semaglutide or Tirzepatide were less than half as likely to die within…
The weight loss drug Gold Rush has entered a new phase. As major telehealth companies scramble to maintain their grip on the lucrative GLP-1 market, they’ve found a creative workaround: “microdosing.” Noom, Found, and Hims & Hers have all recently launched programs offering lower doses of semaglutide and tirzepatide, marketing them as gentler alternatives with…
AbbVie announced it has settled litigation with generic manufacturers in a way that effectively keeps competition for its blockbuster immunology drug Rinvoq off the market until 2037. Let that sink in: patients, payers, and the healthcare system will be forced to pay monopoly prices for another 12 years—not because of scientific innovation, but because of legal maneuvering….